Abstract
Juvenile dermatomyositis (JDM) is a rare, severe, autoimmune disease characterized by a small-vessel vasculopathy that primarily affects skin and muscle, but also lung, joints, gut and heart. Nowadays prompt recognition of this entity and aggressive treatment, when needed, improves outcomes and has decreased mortality that, before corticosteroid became a mainstay in therapy, could reach 40%.
MeSH terms
-
Adrenal Cortex Hormones / therapeutic use
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Murine-Derived / therapeutic use
-
Atrophy
-
Autoantibodies / immunology
-
Capillaries / pathology
-
Child
-
Child, Preschool
-
Cytokines / metabolism
-
Dendritic Cells / metabolism
-
Dendritic Cells / pathology
-
Dermatomyositis* / diagnosis
-
Dermatomyositis* / drug therapy
-
Dermatomyositis* / etiology
-
Dermatomyositis* / immunology
-
Disease Progression
-
Early Diagnosis
-
Humans
-
Immunoglobulins, Intravenous / therapeutic use
-
Immunosuppressive Agents / therapeutic use
-
Infant
-
Infliximab
-
Rituximab
-
Skin / blood supply
-
Skin / pathology
Substances
-
Adrenal Cortex Hormones
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Autoantibodies
-
Cytokines
-
Immunoglobulins, Intravenous
-
Immunosuppressive Agents
-
Rituximab
-
Infliximab